Vector Efficacy Cross-Over Pilot Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Vector Efficacy Cross-Over Pilot Study (NCT04263532), a randomized phase not stated study. The primary outcome is Daytime PaCO2 (Arterial Blood Gas).

2. Clinical Question

This is a study question about a physiologic measurement over a defined treatment period, not a direct measure of symptoms, daily function, or long-term outcomes. The registry also lists ventilator usage, comfort and therapy preference, and serious adverse events among secondary outcomes. Those measures add different perspectives: device use, participant experience, and safety. Their presence does not establish that results for each were posted or analyzed. The record lists four outcome measures, but the number of analyses reported is 0.

3. Trial Design

The record identifies this as a randomized controlled crossover pilot study. Participants were assigned to treatment conditions in a design where a participant may receive more than one condition over time; this is the general meaning of a crossover design. The registry does not report the treatment sequence, period length for each condition, washout interval, or the method used to account for period or sequence effects. Those details are important for interpreting crossover results and are not reported in the registry record.

The study enrolled 21 participants according to the registry. The primary outcome description says that 10 participants were randomized for the described analysis population. It states that 2 participants received standard of care for both arms and were excluded, 2 additional participants discontinued before completing both arms and were excluded, and 1 participant did not contribute PaCO2 data. The description ends mid-sentence after beginning a statement about NIV-naive participants, so the complete account of the analysis population is not reported in the registry record.

The primary outcome results are presented for NIV current users: 5 participants for Vector Device and 5 for Standard of Care NIV. The reported values are means with standard deviations. These group summaries do not by themselves show how the crossover comparison was analyzed, whether observations were paired within participant, or whether period effects were considered.

The study is listed as terminated. Its recorded start date is 2020-01-21 and its primary completion date is 2023-11-17. The sponsor is Philips Clinical and Medical Affairs Global. The record identifies the allocation as randomized and masking as none. The reason for termination, detailed protocol procedures, and any planned analysis approach are not reported in the registry record. A pilot label describes the study type, but it does not establish the precision of the estimates or the rationale for the enrollment target.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 21 participants were consented and screened. 12 participants were screen failures, one of these participants was rescreened and determined to be eligible resulting in 10 participants being enrolled and randomized.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: 10 participants were randomized, 2 participants received Standard of care for both arms, so they were excluded from analysis, 2 additional participants discontinued prior to completing both arms and they were excluded from the analysis. 1 participant did not contribute PaCO2 data. No NIV naive participants were enrolled.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: 21 participants were consented and screened. 12 participants were screen failures, one of these participants was rescreened and determined to be eligible resulting in 10 participants being enrolled.

6. Primary Endpoint

The registry lists the primary outcome as Daytime PaCO2 (Arterial Blood Gas), measured over At the end of the 4-to-6-week period.

The primary endpoint is daytime PaCO2 measured by arterial blood gas, expressed in the record as mmHG. PaCO2 is the partial pressure of carbon dioxide in arterial blood. The endpoint description specifies room-air carbon dioxide levels at the end of 4-to-6 weeks of therapy. The recorded timeframe is the end of the 4-to-6-week period.

This is a continuous physiologic measure: it can take a range of values rather than placing each participant into a simple event category. Reporting a mean describes the central value in a group, while a standard deviation describes how spread out individual measurements are around that mean. Neither summary alone shows the uncertainty in the mean or the uncertainty in a treatment contrast.

As general context, arterial PaCO2 is used to quantify carbon dioxide in arterial blood. A measurement taken after a treatment period can describe the physiologic status at that time. It does not, on its own, describe how a participant feels, how much a device is used, or whether a difference is important to participants. The record separately lists comfort and therapy preference and average 30-day ventilator usage among secondary outcomes.

For current users, the posted means are 59.2 for Vector Device and 49.8 for Standard of Care NIV; the corresponding standard deviations are 16.6 and 8.8. Each condition has 5 participants. The registry does not report a confidence interval or inferential comparison for this endpoint. Consequently, these descriptive values characterize the posted groups but do not establish the precision or statistical significance of a contrast.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Several statistical ideas help distinguish what the posted summaries show from what they cannot establish. The primary endpoint is continuous, and its results are summarized by a mean and standard deviation. The mean is the arithmetic average of measurements in a group. The standard deviation describes the spread of those measurements around their mean. These quantities describe the observed data, but they do not directly quantify uncertainty in a contrast between conditions.

Why does the crossover design matter?

In general, a crossover trial exposes participants to more than one treatment condition, so each participant may contribute measurements under multiple conditions. This can make within-participant comparisons informative because characteristics that remain stable within a person are shared across conditions. The comparison relies on the design and analysis properly accounting for the relationship between repeated measurements. The registry identifies a crossover design but does not report treatment sequence, period-specific results, washout procedures, or an analysis that accounts for repeated measurements. It is therefore not possible to determine from the record whether or how those features were incorporated into the primary analysis.

The reported condition summaries list 5 participants for Vector Device and 5 for Standard of Care NIV among current users. Those counts should not be taken as evidence that the measurements were analyzed as independent groups. In a crossover analysis, the number of participants and the pairing of their measurements matter together. No paired differences, within-participant variability, or analysis estimate is reported. Reconstructing a crossover comparison from separate means and standard deviations is not possible without additional information.

What does a standard deviation tell the reader?

As general explanation, a standard deviation describes how dispersed individual observations are around a group mean. It is not the same as a standard error or confidence interval. A confidence interval is an uncertainty interval around an estimate, and its calculation requires an appropriate analysis and information about variability and sample size. For a crossover contrast, the variability of within-person differences is especially relevant. The posted standard deviations for each condition do not reveal that quantity.

Variation can also affect how well a statistical model describes data. In general, over-dispersion means that the data vary more than a model assumes. It can make standard errors too small if not handled appropriately. The primary endpoint is continuous, and no model details are reported, so the registry provides no basis to say that over-dispersion was assessed or relevant to the reported analysis.

Why is there no inferential comparison?

The registry indicates that a two-arm comparison for the continuous endpoint is missing or not estimable. No p-value, confidence interval, model estimate, or formal test is posted. A p-value, in general, measures how unusual data at least as extreme as those observed would be under a specified null model; it does not measure the probability that a treatment works. A confidence interval would communicate the range of effect values compatible with the analysis. Neither can be inferred from the two means alone.

The sample-size assumptions describe a planning illustration based on the observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect specified as a fraction of the observed effect. These are planning assumptions, not a description of the trial's original design rationale. The registry does not report the trial's own sample-size justification. Planning numbers, when used, are not observed power and should not be interpreted as evidence about the probability that the trial detected an effect.

How should the posted means be used?

The means and standard deviations are useful as descriptive summaries of the posted current-user observations. The standard deviations make clear that participants' measured values were not all identical. However, these summaries do not identify why measurements vary, establish a treatment effect, or give the precision of a comparison. Since the analysis population account is incomplete and there is no inferential estimate, interpretation should remain descriptive.

General statistical practice distinguishes a prespecified analysis plan from a later exploratory calculation. The registry does not report the statistical analysis plan, model specification, covariate adjustment, handling of period effects, interim analyses, or a multiplicity strategy. It would be inappropriate to infer any of these procedures from the design label or the posted group summaries. The analysis count is 0, which indicates no analyses are listed in the record, but it does not reveal why a comparison is absent.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Vector Device (NIV Current Users)", "Standard of Care NIV (NIV Current Users)")
n   <- c(5, 5)
m   <- c(59.2, 49.8)
sp  <- c(16.6, 8.8)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Vector Device (NIV Current Users)  5  59.200  16.600  38.588  79.812
CARM  Standard of Care NIV (NIV Current Users)  5  49.800  8.800  38.873  60.727

11. Multiplicity, Missing Data and Analysis Populations

The registry lists four outcome measures and three secondary outcomes: average 30 Day Ventilator Usage Hours; patient comfort and therapy preference based questionnaire responses; and assessment of unanticipated serious adverse device effects and serious adverse events. The primary outcome is daytime PaCO2. The record reports 0 analyses. It does not provide a multiplicity plan, a hierarchy among outcomes, or indicate which outcomes were prespecified as confirmatory. The handling of multiple comparisons is therefore not reported in the registry record.

As general context, multiplicity arises when several outcomes, time points, subgroups, or treatment contrasts are examined. Repeated testing can increase the chance of finding an apparently notable result by chance. Statistical plans sometimes address this through a hierarchy or adjustment strategy, but no such approach should be assumed. The record does not provide enough information to determine whether multiplicity was considered.

The primary endpoint description says that 10 participants were randomized, 2 participants received Standard of Care for both arms and were excluded from analysis, 2 additional participants discontinued before completing both arms and were excluded, and 1 participant did not contribute PaCO2 data. It then begins a statement about NIV-naive participants but ends before completing it. Thus, the complete flow from randomized participants to the reported analysis population is not reported in the registry record. The condition summaries show 5 participants in each current-user condition, but the relationship between these counts and all exclusions is not fully explained.

Missing-data methods are also not reported. The record does not state whether missing values were imputed, whether a complete-case approach was used beyond the stated exclusions, or how discontinuation affected the analysis. In a crossover study, incomplete treatment periods can limit paired comparisons; the registry identifies two discontinuations before both arms were completed, but does not report how their available data were handled. These omissions limit assessment of the analysis population and the potential influence of missing observations.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: copd exacerbation (10.0%), shortness of breath and left sided chest discomfort (10.0%), hypervolemia (10.0%).

For NIV current users, the registry lists 10 participants at risk for serious adverse events in each condition. It records 3 with serious events for Vector and 0 for Standard of Care NIV. For other adverse events, it lists 2 affected out of 10 at risk in each condition. No deaths are listed in either condition. The record also names COPD exacerbation, shortness of breath and left sided chest discomfort, and hypervolemia among the top serious terms, each shown with 10.0%.

These figures are descriptive counts in a small study. They do not establish that one condition caused an event or that a difference between conditions is reliable. In a crossover design, the same participant may contribute information under multiple conditions; the record does not describe whether adverse-event counts reflect unique participants, episodes, or a comparison that accounts for this structure. The named serious terms are not accompanied by counts by treatment condition, so their distribution across conditions is not reported in the registry record.

As general context, safety counts are interpreted alongside how events were defined, the period of observation, exposure, and the method for attributing events to a condition. Those details are not reported in the registry record. The listed counts are not rates adjusted for time on treatment, and the record provides no inferential comparison. They should be read as reported safety observations, not as a comparative estimate or a conclusion about safety.

13. What the Result Does, and Does Not, Mean

The primary results document mean daytime PaCO2 values for NIV current users under two device-setting conditions at the end of the 4-to-6-week period. The Vector condition has a reported mean of 59.2 and standard deviation of 16.6 among 5 participants. The Standard of Care NIV condition has a reported mean of 49.8 and standard deviation of 8.8 among 5 participants. These figures characterize the posted observations.

They do not, on their own, quantify a statistically supported treatment contrast. The registry does not report a comparison estimate, confidence interval, or p-value, and marks the continuous two-arm comparison as missing or not estimable. Because the study is crossover, the association between measurements from the same participants is relevant, but the record does not provide paired results or describe how repeated measurements were analyzed. A reader cannot recover that information from separate condition means and standard deviations.

The results also do not establish effects in NIV-naive participants. Although the study description includes both current users and NIV-naive participants, the primary outcome population statement is incomplete, and the posted primary condition summaries are explicitly for current users. Nor do the primary values answer questions about comfort, preference, or ventilator usage. Those are listed as secondary outcomes, but the record reports no analyses.

The serious-event figures are likewise descriptive. Counts are reported for current users in each condition, but the record does not provide a formal safety comparison or enough detail to assess event attribution and exposure. A count in one condition and a count in another should not be read as proof of a causal difference.

As general interpretation, statistical evidence and clinical importance are separate questions. Even a precise statistical estimate would need context to establish whether a difference matters to participants; the record does not provide a threshold for meaningful change. With no inferential comparison and only small reported condition groups, the posted data are best understood as limited descriptive evidence. The record does not support a treatment recommendation or a conclusion that either condition is superior.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of the gap between a study design label and the details needed to interpret its results. The record calls the study randomized and crossover, but the posted primary outcome information consists of separate condition means and standard deviations. In crossover studies, within-person comparisons can be central; without paired results or an analysis description, readers cannot determine how the design informed the estimate.

The record also illustrates why participant flow matters. It describes exclusions and discontinuations, but the primary population description is truncated. The reported condition summaries each include 5 current users, yet the complete relationship between randomization, exclusions, and analysis is not available. Clear reporting of the analysis population helps readers judge how representative the analyzed observations are of those randomized.

Another statistical lesson is that descriptive results are not the same as an inferential comparison. Means and standard deviations can characterize observed data, but they do not supply an uncertainty interval or test for a contrast. The registry explicitly has no analyses listed and indicates that a two-arm comparison is missing or not estimable. This makes it important to distinguish the posted values from a treatment-effect claim.

Finally, the study has multiple outcome domains: physiology, device usage, participant experience, and safety. Each addresses a different question, and a complete analysis plan would clarify how they were prioritized and interpreted together. The registry does not report that plan or multiplicity methods. These reporting gaps do not erase the descriptive observations, but they limit what can be learned from them and underline the value of transparent methods alongside results.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The number of participants in the posted current-user primary results is 5 per condition. Such small groups provide limited information about the range of possible measurements, and individual observations may have substantial influence. The reported standard deviations show variability, but do not provide the uncertainty of the treatment contrast.

The study is crossover, yet the record does not report treatment sequence, period-specific results, washout procedures, or an analysis accounting for repeated measurements. The posted condition summaries do not allow reconstruction of paired differences. The registry marks the two-arm continuous comparison as missing or not estimable and lists 0 analyses, so the primary endpoint has no reported inferential estimate.

The primary outcome population description is incomplete. It reports exclusions and discontinuations, then ends mid-sentence. The complete analysis population, including the role of NIV-naive participants, is not reported in the registry record. Missing-data handling and the effect of incomplete crossover participation are also not reported.

The registry lists secondary outcomes but reports no analyses. It does not report the statistical analysis plan, multiplicity approach, outcome hierarchy, interim analyses, or the study's own sample-size justification. The reason for termination is not reported. These limitations constrain interpretation of both efficacy-related summaries and safety counts. The results are descriptive and should not be generalized beyond the participants and conditions represented in the posted data without additional evidence.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Vector Efficacy Cross-Over Pilot Study — NCT04263532.
• Registry record last updated 2025-05-09; status last verified 2025-05.
• Results first posted 2025-05-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The record describes NCT04263532, the Vector Efficacy Cross-Over Pilot Study, a randomized, unmasked crossover study sponsored by Philips Clinical and Medical Affairs Global. It enrolled 21 participants and is listed as terminated. The recorded start date is 2020-01-21 and primary completion date is 2023-11-17.

The primary endpoint was daytime arterial blood gas PaCO2 at the end of the 4-to-6-week period. For current users, the record reports a mean of 59.2 with standard deviation 16.6 for Vector and a mean of 49.8 with standard deviation 8.8 for Standard of Care NIV, with 5 participants in each condition. A two-arm comparison is missing or not estimable, and no analyses are listed.

Secondary outcomes include ventilator usage, comfort and therapy preference, and serious adverse events. The registry reports descriptive safety counts for current users but no comparative safety analysis. The full primary analysis population description, statistical plan, missing-data methods, and reason for termination are not reported in the registry record.